RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Redhill Biopharma Ltd.

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.